• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

The Argument for Caution When Judging Industry Payments to Dermatology Clinical Guideline Authors

Article

After a study reported that physicians who authored dermatology clinical guidelines didn't always fully disclose financial conflicts of interest, the American Academy of Dermatology urged the public to view the findings with caution.

The public should view with caution the recent findings that authors of dermatology clinical practice guidelines (CPGs) may be receiving industry payments that they don’t fully disclose, according to a statement from the American Academy of Dermatology (AAD).

JAMA Dermatology published a study last week that raised concerns over potential financial conflicts of interest among physicians who help create dermatology CPGs. AAD responded to the study, and its president, Henry W. Lim, MD, FAAD, said that dermatologists who author guidelines are the experts in their field, and as such they often engage with companies on the cutting edge of research.

“In evaluating potential conflicts of interest among guidelines authors, the AAD does not consider research activities to be conflicts, as these activities are vital in advancing clinical knowledge and fueling dermatologic innovation,” Lim explained.

The study, and AAD, both noted that it was not clear how, or if, these industry payments influenced the physicians involved in the development of dermatology guidelines, and the study only assessed if the payments were relevant if the company made products related to the guideline. However, those physician relationships could be unrelated.

In an editorial that accompanied the study, Kenneth A. Katz, MD, MSc, MSCE, of Kaiser Permanente, explained that the question of industry ties among authors of CPGs is important, because “CPGs influence decision making by physicians, patients, and insurers.”

However, Katz raises 3 questions:

  1. Are the results valid? It’s not clear, he determined based on the literature search, the determination of the relevance of a manufacturer’s products to a CPG, and the version of regulations cited in the study.
  2. Does it matter if CPG authors received payments? The study doesn’t address the question, although Katz said that the answer is likely “yes.”
  3. What should be done? The study authors urged increased transparency and enforcement of payment policies and procedures.

“The AAD stands by the strength and accuracy of its clinical guidelines, as well as the regulations in place to minimize the influence of potential conflicts of interest on the guidelines process,” Lim said. “While we maintain the guidelines studied in this paper were created in compliance with those regulations, we take seriously this issue, and continue to evaluate and refine our guidelines process to address both real and perceived potential conflicts of interest.”

Related Videos
Dr Michael Morse, Duke University
Video 10 - "Bronchiectasis Exacerbation Management"
video 10  - "Developing Practical Solutions to Improve Cardiovascular Care"
video 10  - "Developing Practical Solutions to Improve Cardiovascular Care"
Video 6 - "Optimal Approaches to Diagnostic Testing for Type 1 Diabetes Mellitus"
Video 13 - "Concluding Thoughts on Ph+ ALL Treatment"
Video 12 - "The Future of Ph+ ALL Treatments"
dr lawrence eichenfield
dr krystyn van vliet
Raajit Rampal, MD, PhD, screenshot
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.